RxDoctor Payments DataLook up a doctor →

Barbara Chamness

Family · Colorado Springs, CONPI 1366951972

Payments from drug & device makers

$14,510in general payments, 2019–2025

Across 587 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Boehringer Ingelheim$1K
  • Sanofi$1K
  • United Therapeutics Corporation$827
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$1,47910%
  • Food & beverage$12,64587%
  • Education$3863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,510 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$65,955
Medicare patients
345
Services billed
573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter262$238,915
Prolastin CAlpha-1-Proteinase Inhibitor12$89,801
Spiriva RespimatTiotropium Bromide121$81,161
Dupixent PenDupilumab11$63,757
Breztri AerosphereBudesonide/Glycopyr/Formoterol76$58,966
Breo ElliptaFluticasone/Vilanterol78$42,282
SymbicortBudesonide/Formoterol Fumarate135$40,917
Stiolto RespimatTiotropium Br/Olodaterol Hcl66$38,218
Spiriva HandihalerTiotropium Bromide36$33,221
Advair HfaFluticasone Propion/Salmeterol53$22,020
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$20,502
Fluticasone-SalmeterolFluticasone Propion/Salmeterol67$11,307
Albuterol Sulfate HfaAlbuterol Sulfate303$10,228
Wixela InhubFluticasone Propion/Salmeterol47$7,550
Incruse ElliptaUmeclidinium Bromide17$5,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$2,135$307,247386 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,466$119,379187 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,055$99,883211 claims
Grifols USA, LLCProlastin C$755$89,80112 claims
MerckDulera$326$4,30811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →